Tag: sunitinib

1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such as sunitinib, was associated with clinical benefit and well tolerated in drug-naïve patients with advanced refractory gastrointestinal stromal tumors. 2. This combination therapy achieved better global disease control and allowed...
1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such as sunitinib, was associated with clinical benefit and well tolerated in drug-naïve patients with advanced refractory gastrointestinal stromal tumors. 2. This combination therapy achieved better global disease control and allowed...
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). 2. Occurrence of grade 3 or 4 adverse events were similar among patients in the cabozantinib and sunitinib groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Papillary renal cell carcinoma (PRCC) is among the most...
1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma 2. The combination treatment caused more drug discontinuation compared to sunitinib. Evidence Rating Level: 1 (Excellent) Study Rundown: In advanced renal-cell carcinoma, sunitinib is the standard of care, but the landscape of different regimens is evolving....
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). 2. Occurrence of grade 3 or 4 adverse events were similar among patients in the cabozantinib and sunitinib groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Papillary renal cell carcinoma (PRCC) is...
Image: PD  1. Pazopanib and sunitinib showed similar efficacy in treating metastatic renal-cell carcinoma as a first-line therapy.  2. Quality-of-life measures generally favored pazopanib. Toxicity profiles were mixed.  Evidence Rating Level: 2 (Good)             Study Rundown: This study demonstrated that pazopanib has more favorable quality-of-life outcomes compared to sunitinib...